Tardive dyskinesia and new antipsychotics
暂无分享,去创建一个
[1] C. Correll,et al. One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. , 2007, Journal of child and adolescent psychopharmacology.
[2] Geoff M. Anderson,et al. Antipsychotic Medications and Drug‐Induced Movement Disorders Other Than Parkinsonism: A Population‐Based Cohort Study in Older Adults , 2005, Journal of the American Geriatrics Society.
[3] D. Swingler,et al. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa , 2005, Schizophrenia Research.
[4] Jane S. Paulsen,et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. , 1995, Archives of general psychiatry.
[5] C. Correll,et al. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. , 2004, The American journal of psychiatry.
[6] W. Glazer,et al. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. , 1993, Archives of general psychiatry.
[7] J. Leon. The effect of atypical versus typical antipsychotics on tardive dyskinesia , 2006, European Archives of Psychiatry and Clinical Neuroscience.
[8] R. Findling,et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. , 2004, The American journal of psychiatry.
[9] A. Bulbena,et al. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. , 2000, Journal of clinical psychopharmacology.
[10] J. Lieberman,et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. , 1998, The American journal of psychiatry.
[11] I. Augustyns,et al. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. , 2006, European child & adolescent psychiatry.
[12] J. Lieberman,et al. Prospective study of tardive dyskinesia incidence in the elderly. , 1991, JAMA.
[13] H. Youssef,et al. Morbidity and mortality in tardive dyskinesia: associations in chronic schizophrenia , 1987, Acta psychiatrica Scandinavica.
[14] D. Jeste,et al. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. , 1999, The American journal of psychiatry.
[15] June Corwin,et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. , 2003, JAMA.
[16] P. Gaszner,et al. Clozapine maintenance therapy in schizophrenia , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[17] F. Goodwin,et al. Extrapyramidal side effects with atypical neuroleptics in bipolar disorder , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[18] A. Lane,et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia , 1996, Acta psychiatrica Scandinavica.
[19] G. Chouinard,et al. Manual for the Extrapyramidal Symptom Rating Scale (ESRS) , 2005, Schizophrenia Research.
[20] J. van Os,et al. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. , 2006, The American journal of psychiatry.
[21] R. Findling,et al. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. , 2005, Journal of the American Academy of Child and Adolescent Psychiatry.
[22] J. Lieberman,et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.
[23] Philip D. Harvey,et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. , 2005, The American journal of psychiatry.
[24] C. Arango-Dávila,et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. , 2005, The Journal of clinical psychiatry.
[25] Stefan Leucht,et al. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. , 2002, The American journal of psychiatry.
[26] G. Gardos,et al. Five-year follow-up study of tardive dyskinesia. , 1985, Advances in biochemical psychopharmacology.
[27] I. Augustyns,et al. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. , 2006, Journal of child and adolescent psychopharmacology.
[28] J. de Leon. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. , 2007, European archives of psychiatry and clinical neuroscience.
[29] J. Doucette,et al. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. , 1993, The Journal of clinical psychiatry.
[30] J. van Os,et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. , 2005, The Journal of clinical psychiatry.
[31] E. Lindström,et al. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course , 2006, International clinical psychopharmacology.
[32] J. Lieberman,et al. Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial , 2005, Schizophrenia Research.
[33] G. Gharabawi,et al. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: Results from a long-term study , 2005, Schizophrenia Research.
[34] J. Kane,et al. Research diagnoses for tardive dyskinesia. , 1982, Archives of general psychiatry.
[35] S. Leucht,et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis , 2003, The Lancet.
[36] J. Mcgrath,et al. The treatment of tardive dyskinesia—a systematic review and meta-analysis , 1999, Schizophrenia Research.
[37] Peter B. Jones,et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). , 2006, Archives of general psychiatry.
[38] M. Borenstein,et al. Incidence of tardive dyskinesia: five-year data from a prospective study. , 1984, Psychopharmacology bulletin.
[39] I. Glick,et al. A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.